Ursodeoxycholate sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H561060

CAS#: 2898-95-5 (sodium)

Description: Ursodeoxycholate sodium, also known as Ursodeoxycholic Acid (sodium salt) and UDCA sodium, has anti-inflammatory and cytoprotective properties. UDCA sodium is a naturally occurring secondary bile acid. UDCA sodium is an FDA-approved drug for cholestatic liver disorders.

Chemical Structure

img
Ursodeoxycholate sodium
CAS# 2898-95-5 (sodium)
Instruction

Theoretical Analysis

Hodoodo Cat#: H561060
Name: Ursodeoxycholate sodium
CAS#: 2898-95-5 (sodium)
Chemical Formula: C24H39NaO4
Exact Mass: 414.27
Molecular Weight: 414.560
Elemental Analysis: C, 69.53; H, 9.48; Na, 5.55; O, 15.44

Price and Availability

Size Price Availability Quantity
2g USD 450
5g USD 650
10g USD 950
Bulk inquiry

Related CAS #: 128-13-2 (free acid)   2898-95-5 (sodium)    

Synonym: UDCA sodium, UDCA Na, Sodium Ursodeoxycholate; Ursodeoxycholic Acid (sodium salt)

IUPAC/Chemical Name: sodium (R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate

InChi Key: WDFRNBJHDMUMBL-FUXQPCDDSA-M

InChi Code: InChI=1S/C24H40O4.Na/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26;/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-;/m1./s1

SMILES Code: C[C@@H]([C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)CCC(O[Na])=O

Appearance: Crystalline solid

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 414.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Manley S, Ding W. Role of farnesoid X receptor and bile acids in alcoholic liver disease. Acta Pharm Sin B. 2015 Mar;5(2):158-67. doi: 10.1016/j.apsb.2014.12.011. Epub 2015 Mar 9. Review. PubMed PMID: 26579442; PubMed Central PMCID: PMC4629219.

2: Ding L, Yang L, Wang Z, Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B. 2015 Mar;5(2):135-44. doi: 10.1016/j.apsb.2015.01.004. Epub 2015 Feb 25. Review. PubMed PMID: 26579439; PubMed Central PMCID: PMC4629217.

3: Jones H, Alpini G, Francis H. Bile acid signaling and biliary functions. Acta Pharm Sin B. 2015 Mar;5(2):123-8. doi: 10.1016/j.apsb.2015.01.009. Epub 2015 Feb 19. Review. PubMed PMID: 26579437; PubMed Central PMCID: PMC4629225.

4: Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015 Apr;62(1 Suppl):S25-37. doi: 10.1016/j.jhep.2015.02.023. Review. PubMed PMID: 25920087.

5: Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol. 2014 Mar;4(1):25-36. doi: 10.1016/j.jceh.2013.10.005. Epub 2013 Nov 23. Review. PubMed PMID: 25755532; PubMed Central PMCID: PMC4017198.

6: Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015 Aug;62(2):635-43. doi: 10.1002/hep.27744. Epub 2015 Mar 23. Review. PubMed PMID: 25678132; PubMed Central PMCID: PMC4515188.

7: Baghdasaryan A, Chiba P, Trauner M. Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med. 2014 Jun;37:57-76. doi: 10.1016/j.mam.2013.12.001. Epub 2013 Dec 12. Review. PubMed PMID: 24333169; PubMed Central PMCID: PMC4045202.

8: Hofmann AF. Bile acids as drugs: principles, mechanisms of action and formulations. Ital J Gastroenterol. 1995 Mar;27(2):106-13. Review. PubMed PMID: 7579591.

9: Scharschmidt BF, Lake JR. Hepatocellular bile acid transport and ursodeoxycholic acid hypercholeresis. Dig Dis Sci. 1989 Dec;34(12 Suppl):5S-15S. Review. PubMed PMID: 2689116.